Co-Founder and Scientific Director

Dr Loddo is responsible for directing all technical and scientific aspects of the clinical services, contract research activities and administrative/operational matters of the company. He also directs the development of strategies to ensure effective achievement of scientific/business objectives, including planning, implementation, monitoring and evaluating the delivery of clinical services, completion of contract research tasks and projects, development of commercial and financial strategies for capital expenditures, staff resources, marketing, and contracts.

Dr Marco Loddo BSc, PhD undertook his post-graduate training in Professor Williams’ laboratory within the Department of Pathology at University College London in which he combined anatomical pathology, cell cycle research and functional genomics to identify new diagnostic and therapeutic intervention strategies for the improved clinical management of cancer patients.

During the last decade at UCL he has directed the research and development of novel diagnostic approaches for predicting response to molecularly targeted agents against the oncogenic growth signalling pathways and cell cycle machinery. His research has focused on exploiting the DNA replication initiation machinery and mitotic regulators to identify new translational theranostic opportunites to support the new era of personalised medicine. This multi-disciplinary research has generated a number of discoveries in relation to cancer screening and predictive testing for anti-cancer agents in solid tumours. These discoveries have been patented, commercialised by biopharma and are currently undergoing clinical trials. In addition to the diagnostic applications, his research identified a number of potent anti-cancer targets that are now being developed in-house within the R&D arm of Oncologica.

Dr Loddo’s background and experience includes biomarker discovery and validation, development of companion diagnostics for molecularly targeted therapies, translational medicine and clinical trials. Dr Loddo has now brought this wealth of experience in molecular pathology analytics and targeted therapies to Oncologica in his role as the Scientific Director for the company.